Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 1.6 Million AUD | 15.61% |
| 2023 | 1.38 Million AUD | -8.28% |
| 2022 | 1.51 Million AUD | 6.97% |
| 2021 | 1.41 Million AUD | 1188847.06% |
| 2020 | -119.00 AUD | -100.01% |
| 2019 | 1.06 Million AUD | 9999.78% |
| 2018 | -10.71 Thousand AUD | -100.65% |
| 2017 | 1.64 Million AUD | 7.42% |
| 2016 | 1.53 Million AUD | -8.34% |
| 2015 | 1.67 Million AUD | -2.92% |
| 2014 | 1.72 Million AUD | 93.11% |
| 2013 | 891.95 Thousand AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | -100.0% |
| 2007 | 402.45 Thousand AUD | -49.37% |
| 2006 | 794.86 Thousand AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | -100.0% |
| 2002 | 62.74 Thousand AUD | 380.4% |
| 2001 | 13.06 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | - AUD | -100.0% |
| 2024 Q4 | -18.79 Thousand AUD | 0.0% |
| 2024 FY | -40.49 Thousand AUD | -102.92% |
| 2024 Q1 | 822.55 Thousand AUD | 4049.28% |
| 2024 Q2 | 800.85 Thousand AUD | -2.64% |
| 2023 FY | 1.38 Million AUD | -8.28% |
| 2023 Q2 | 693.12 Thousand AUD | -3.15% |
| 2023 Q1 | 715.64 Thousand AUD | -5.45% |
| 2023 Q3 | - AUD | -100.0% |
| 2023 Q4 | -20.82 Thousand AUD | 0.0% |
| 2022 Q4 | 756.87 Thousand AUD | -2.87% |
| 2022 Q3 | 779.26 Thousand AUD | 3507.51% |
| 2022 FY | 1.51 Million AUD | 6.97% |
| 2022 Q1 | - AUD | -100.0% |
| 2022 Q2 | -22.86 Thousand AUD | 0.0% |
| 2021 Q3 | 705.97 Thousand AUD | 51809.78% |
| 2021 Q1 | 25 Thousand AUD | -93.39% |
| 2021 Q4 | 682.27 Thousand AUD | -3.36% |
| 2021 FY | 1.41 Million AUD | 1188847.06% |
| 2021 Q2 | 1360.00 AUD | -94.56% |
| 2020 Q2 | -27.03 Thousand AUD | 0.0% |
| 2020 Q4 | 378.42 Thousand AUD | -5.75% |
| 2020 FY | -119.00 AUD | -100.01% |
| 2020 Q1 | - AUD | 100.0% |
| 2020 Q3 | 401.51 Thousand AUD | 1585.43% |
| 2019 FY | 1.06 Million AUD | 9999.78% |
| 2019 Q4 | -4592.00 AUD | 0.0% |
| 2019 Q3 | - AUD | -100.0% |
| 2019 Q2 | 536.41 Thousand AUD | 0.0% |
| 2019 Q1 | 536.41 Thousand AUD | 115258.28% |
| 2018 Q1 | 810.82 Thousand AUD | -2.28% |
| 2018 FY | -10.71 Thousand AUD | -100.65% |
| 2018 Q4 | 465.00 AUD | 0.0% |
| 2018 Q3 | 465.00 AUD | -99.94% |
| 2018 Q2 | 810.82 Thousand AUD | -0.0% |
| 2017 FY | 1.64 Million AUD | 7.42% |
| 2017 Q4 | 829.74 Thousand AUD | 0.0% |
| 2017 Q3 | 829.74 Thousand AUD | 0.0% |
| 2017 Q1 | - AUD | -100.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 Q4 | 774.09 Thousand AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q1 | - AUD | -100.0% |
| 2016 FY | 1.53 Million AUD | -8.34% |
| 2016 Q3 | 774.09 Thousand AUD | 0.0% |
| 2015 Q4 | 836.13 Thousand AUD | 0.0% |
| 2015 Q3 | 836.13 Thousand AUD | 0.0% |
| 2015 FY | 1.67 Million AUD | -2.92% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 Q1 | - AUD | -100.0% |
| 2014 FY | 1.72 Million AUD | 93.11% |
| 2014 Q3 | 861.24 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q1 | - AUD | -100.0% |
| 2014 Q4 | 861.24 Thousand AUD | 0.0% |
| 2013 FY | 891.95 Thousand AUD | 0.0% |
| 2013 Q3 | 445.97 Thousand AUD | 0.0% |
| 2013 Q4 | 445.97 Thousand AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | -100.0% |
| 2007 FY | 402.45 Thousand AUD | -49.37% |
| 2006 FY | 794.86 Thousand AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2003 FY | - AUD | -100.0% |
| 2002 FY | 62.74 Thousand AUD | 380.4% |
| 2001 FY | 13.06 Thousand AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 89.302% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -51628.433% |
| SQZ Biotechnologies Company | 9.79 Million USD | 83.616% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 86.292% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 98.653% |
| Mesoblast Limited | -35.16 Million USD | 104.563% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 4798.729% |
| Genus plc | 178.7 Million USD | 99.102% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -291.212% |
| Marizyme, Inc. | 457.7 Thousand USD | -250.581% |
| ContraFect Corporation | -154 Thousand USD | 1141.958% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 14687.418% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 3309.232% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1990.405% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -2341.297% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 514.093% |
| MultiCell Technologies, Inc. | 49.32 USD | -3253379.319% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 96.015% |
| EV Biologics, Inc. | 48.9 Thousand USD | -3181.423% |
| Q BioMed Inc. | -8988.00 USD | 17952.87% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 94.321% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 10503.371% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.271% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -2192.309% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 1391.431% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -2478.691% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 32503.393% |
| Arch Therapeutics, Inc. | -2439.00 USD | 65889.914% |
| IMV Inc. | -962.29 Thousand USD | 266.748% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -1042.075% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1745.507% |
| GB Sciences, Inc. | -624.00 USD | 257250.0% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 1965.225% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.979% |
| Halberd Corporation | -208.00 USD | 771550.0% |
| Enzolytics Inc. | 30.7 Thousand USD | -5125.401% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -18.235% |
| SYBLEU INC | 11.69 Thousand USD | -13619.357% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -232.609% |
| argenx SE | 1.1 Billion USD | 99.855% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 106.22% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -159.906% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.608% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 18218.97% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 96.383% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 240.562% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -62.414% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 83.304% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 2013.697% |
| BioStem Technologies, Inc. | 15.42 Million USD | 89.597% |
| ONE Bio Corp. | 20.12 Million USD | 92.027% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 13658.226% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 3425.009% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -808.822% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -808.822% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 411.873% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 354.645% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 5633.159% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -256.547% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 602.216% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 65.178% |
| Bioxytran, Inc. | -8285.00 USD | 19467.725% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 530.192% |
| Neutra Corp. | 14.33 Thousand USD | -11093.694% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 2056.849% |
| PureTech Health plc | -1.6 Million USD | 200.101% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 260.264% |
| IXICO plc | 3.27 Million USD | 50.929% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 331.213% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 189.593% |
| CSL Limited | 7.7 Billion USD | 99.979% |
| Cellectis S.A. | 18 Thousand USD | -8814.533% |